



Times subject to small changes based on the final event production. All times in U.S. PDT.



***28<sup>th</sup> Annual Prostate Cancer Foundation  
Scientific Retreat***

***October 28 - 29, 2021  
November 4 - 5, 2021***



# AGENDA

**Thursday, October 28, 2021**  
**\*All times in U.S. PDT**

## VIRTUAL POSTER SESSION

**Starting on Thursday October 28, 2021, 12:01 AM U.S. PDT**

## GENERAL SESSIONS

### **Welcome & Opening Remarks**

**7:00 AM - 7:10 AM**

**Howard Soule, PhD**  
Prostate Cancer Foundation

### **Session 1: Dr. Andrew Hruszkewycz Memorial Session on Measuring and Targeting Lineage Plasticity to Prevent Lethal Prostate Cancer**

**7:10 AM - 8:30 AM**

**Moderator: Andrew Armstrong, MD, ScM**  
Duke University

#### ***A Tale of Two Evasions: Lineage Plasticity and Tumor Heterogeneity***

**Ping Mu, PhD**  
UT Southwestern Medical Center at Dallas

#### ***Measuring CRPC Cellular Heterogeneity at the Single Cell Level to Inform Treatment Strategies***

**Eliezer Van Allen, MD, PhD**  
Harvard: Dana Farber Cancer Institute

#### ***Measuring Lineage Plasticity and Heterogeneity in mCRPC with Liquid Biopsies to Inform Treatment***

**Andrew Armstrong, MD, ScM**  
Duke University

**Thursday, October 28, 2021**

***Targeting Transformed Neuroendocrine Cells to Overcome Treatment Resistance***

**Amina Zoubeidi, PhD**

Vancouver Prostate Centre, Canada

**Followed by Live Session Discussion**

8:30 AM - 8:45 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

**Session 2: Therapeutic Degradors as a New Class of Prostate Cancer Treatments**

**8:45 AM - 9:25 AM**

**Moderator: Howard Soule, PhD**

Prostate Cancer Foundation

***Targeting Enhancer Addiction in Prostate Cancer by Impeding Chromatin Accessibility***

**Arul M. Chinnaiyan, MD, PhD**

University of Michigan, Michigan Center for Translational Pathology

***Clinical Development of ARV-110, a Novel AR Degradar, in Prostate Cancer***

**Debbie Chirnomas, MD, MPH**

Arvinas, Inc.

**Followed by Live Session Discussion**

9:25 AM - 9:40 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

**Session 3: PSMA Theranostics: The New Age of Prostate Cancer Imaging and Treatment**

**9:40 AM - 12:00 PM**

**Moderator: Michael Hofman, MBBS**

Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia

***LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer***

**Michael Hofman, MBBS**

Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia

**Thursday, October 28, 2021**

***Results from the PRINCE Trial: Testing the Combination of LuPSMA with Pembrolizumab in mCRPC***

**Shahneen Sandhu, MBBS**

Peter MacCallum Cancer Centre, Australia

***Targeting Micro-Metastatic Disease with Auger or Alpha Emitters***

**Ana Kiess, MD, PhD**

Johns Hopkins University

***The Four Sisters of Terbium: PET & SPECT Imaging and Targeted Alpha- & Beta-Therapy***

**Cristina Müller, PhD, PD**

Paul Scherrer Institute, Switzerland

***aPROMISE: An Artificial Intelligence Platform to Assist in Standardizing the Detection, Localization and Quantification of Prostate Cancer in PYLARIFY PSMA Scans***

**Bela Denes, MD**

Lantheus Medical Imaging

***Targeting Fibroblast Activation Protein-alpha (FAP) in Prostate Cancer: Is FAP the Next Theranostic Target after PSMA in Prostate Cancer?***

**Andy Simmons, PhD**

Clovis Oncology

***Insights & Future Predictions from 25 Years of PSMA Research***

**Neil Bander, MD**

Weill Cornell Medical College

**Followed by Live Session Discussion**

**12:00 PM - 12:15 PM** ***BREAK, Please Return to the Virtual Lobby to Join the Live Poster Discussion Session***

**VIRTUAL POSTER SESSION 1**

**12:15 PM - 1:45 PM**

**Come to the Poster Hall for Live Discussions  
with Virtual Poster Session 1 Presenters**

**PATIENT ROUNDTABLE: Live from the PCF Scientific Retreat**

**1:00 PM - 3:00 PM**

**END DAY**

**Friday, October 29, 2021**

**Session 4: Prostate Cancer Disparities**

**7:00 AM - 8:40 AM**

**Moderator: Kosj Yamoah, MD, PhD**

Moffitt Cancer Center

***Overview on Prostate Cancer Disparities in African Americans:  
Lessons from the VA Health System and VANDAAM Study***

**Kosj Yamoah, MD, PhD**

Moffitt Cancer Center

**Isla Garraway, MD, PhD**

University of California, Los Angeles; VA Greater Los Angeles Healthcare System

***Epidemiologic Aspects of Prostate Cancer in Black Men and Men of African Ancestry***

**Lorelei Mucci, ScD**

Harvard T.H. Chan School of Public Health

***Disparities in Metastatic Prostate Cancer and Opportunities to Exploit Biology to Improve Outcomes***

**Franklin Huang MD, PhD**

University of California, San Francisco

***Evidence and Solutions in Access with Equitable Health Care as a Contributor to Prostate Cancer Disparities***

**Brandon Mahal, MD**

University of Miami

***The Importance of Clinical Trial Diversity & Lessons from the COVID-19 Vaccine Trial***

**Sandra Amaro, MBA**

Pfizer

**Followed by Live Session Discussion**

**8:40 AM - 8:55 AM**

***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

**Friday, October 29, 2021**

**Session 5: Prostate Cancer Survivorship**

**8:55 AM - 10:50 AM**

**Moderator: Alicia Morgans, MD, MPH**

Harvard: Dana-Farber Cancer Institute

***Prostate Cancer Survivorship: New Programs and Strategies***

**Alicia Morgans, MD, MPH**

Harvard: Dana-Farber Cancer Institute

***Updates and Preliminary Results from the PCF-SURECaP Survivorship Working Group Initiatives: COGCaP and ARACOG***

**Charles J. Ryan, MD**

University of Minnesota; Prostate Cancer Foundation

***Sleep Dysfunction and Prostate Cancer***

**Stacy Loeb, MD, MSc, PhD (Hon)**

New York University; Manhattan Veterans Affairs Hospital

***Utilization of an "Exercise is Medicine" Approach to Optimize Treatment and Health Outcomes among Prostate Cancer Survivors***

**Christina Dieli-Conwright, PhD, MPH**

Harvard: Dana-Farber Cancer Institute

***Prostate Cancer Survivorship at the VA: Leveraging Existing Veterans' Data to Improve Cardiovascular and Bone Health***

**Ravi Parikh, MD, MPP**

University of Pennsylvania; The Corporal Michael J. Crescenz VA Medical Center

***Patient Perspective - ADT, Exercise and QoL***

**Joël Pointon, MPH**

Patient and Advocate

**Followed by Live Session Discussion**

**Special Lecture: ADT and CV Risk: Why Relugolix?**

**10:50 AM - 11:05 AM**

**Neal Shore, MD**

Carolina Urologic Research Center

GenesisCare, US

*Introduced and Moderated by Howard Soule, PhD*

*Prostate Cancer Foundation*

**Followed by Live Discussion**

**Friday, October 29, 2021**

11:05 AM - 11:20 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

**Session 6: Predicting Risk of Prostate Cancer with Polygenic Scores**

**11:20 AM - 12:20 PM**

**Moderator: Tyler Seibert, MD, PhD**  
University of California, San Diego

***Genetic Risk Prediction for Prostate Cancer***

**Christopher Haiman, ScD**  
University of Southern California

***Genetic Risk Stratification for Prostate Cancer: Genomics, Ancestry, and Disparities***

**Tyler Seibert, MD, PhD**  
University of California, San Diego

***A Healthy Lifestyle in Men with a High Prostate Cancer Polygenic Risk Score***

**Anna Plym, PhD**  
Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health

**Followed by Live Session Discussion**

12:20 PM - 12:30 PM ***BREAK, Please Return to the Virtual Lobby to Join the Live Poster Discussion Session***

**VIRTUAL POSTER SESSION 2**

**12:30 PM - 2:00 PM**

**Come to the Poster Hall for Live Discussions  
with Virtual Poster Session 2 Presenters**

**END DAY**

**Thursday, November 4, 2021**

**Session 7: Next Generation Precision Medicine**

**7:00 AM - 8:20 AM**

**Moderator: Paul Boutros, PhD**  
University of California, Los Angeles

***A Multi-Omic Perspective on Localized Prostate Cancer***

**Paul Boutros, PhD**  
University of California, Los Angeles

***A Multi-Omic Perspective on mCRPC***

**Felix Feng, MD**  
University of California, San Francisco

***Using Genomics and Histopathology to Understand Therapeutic Responses in Prostate Cancer***

**Joel Greshock**  
Janssen Oncology

***Lessons from Esophageal Cancer Genomics***

**Rebecca Fitzgerald, PhD**  
University of Cambridge, United Kingdom

**Followed by Live Session Discussion**

**8:20 AM - 8:35 AM**    ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

**PCF WOMEN IN SCIENCE AWARD LECTURE: Tumor Suppressors Reimagined: Converting Understanding of RB Action into Translational Potential**

**8:35 AM - 9:10 AM**

**Karen Knudsen, MBA, PhD**  
American Cancer Society

*Introduced and moderated by Andrea Miyahira, PhD and Howard Soule, PhD  
Prostate Cancer Foundation*

**Followed by Live Discussion**



**Thursday, November 4, 2021**

**KEYNOTE ADDRESS**

**9:10 AM - 10:10 AM**

**Michael Milken**

Founder and Chairman  
Prostate Cancer Foundation

*Introduced by Stuart Holden, MD  
Prostate Cancer Foundation*

10:10 AM - 10:25 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

**SPECIAL LECTURE: Oncology: A Storied Past and Portentous Future**

**10:25 AM - 11:00 AM**

**Anna Barker, PhD**

Lawrence J. Ellison Institute for Transformative Medicine of the University of  
Southern California

*Introduced and moderated by Howard Soule, PhD  
Prostate Cancer Foundation*

**Followed by Live Discussion**

**SPECIAL LECTURE**

**11:00 AM - 11:40 AM**

**PCF 3.0: Serving the Science, the Scientist and the Patient**

**Charles J. Ryan, MD**

Prostate Cancer Foundation

*Introduced and moderated by Howard Soule, PhD  
Prostate Cancer Foundation*

**Followed by Live Discussion**

**Thursday, November 4, 2021**

**Session 8: Glucocorticoid Receptor Biology in Castration Resistant Prostate Cancer**

**11:40 AM -12:40 PM**

**Moderator: Nima Sharifi, MD**  
Cleveland Clinic

***Acquired Defects in Glucocorticoid Metabolism in Enzalutamide-Resistant Prostate Cancer***

**Nima Sharifi, MD**  
Cleveland Clinic

***Targeting the Glucocorticoid Receptor Pathway in CRPC***

**Suzanne D. Conzen, MD**  
UT Southwestern Medical Center

***Diverse Roles of the Androgen Receptor in Breast and Prostate Cancer***

**Wayne Tilley, PhD**  
University of Adelaide, Australia

**Followed by Live Session Discussion**

**12:40 PM - 1:00 PM** ***BREAK, Please Return to the Virtual Lobby to Join the Live Poster Discussion Session***

**VIRTUAL POSTER SESSION 3**

**1:00 PM - 2:30 PM**

**Come to the Poster Hall for Live Discussions  
with Virtual Poster Session 3 Presenters**

**END DAY**

**Friday, November 5, 2021**

**Session 9: Real World Evidence and Synthetic/Virtual Control Arms**

**7:00 AM - 8:00 AM**

**Moderator: Julie Lynch, PhD, RN, MBA**

VINCI Precision Medicine, Salt Lake City VA & University of Utah

***Opportunities and Pitfalls of Conducting Prostate Cancer Research using Big Data in the VA***

**Julie Lynch, PhD, RN, MBA**

VINCI Precision Medicine, Salt Lake City VA & University of Utah

***Analysis of the VA Prostate Cancer Data: A Valuable Resource that can now be Leveraged by Everyone***

**Tito Fojo, MD, PhD**

Columbia University and the James J. Peters VAMC

***Using Real World Evidence to Drive Stakeholder Decisions in Oncology***

**Michael Spencer, MSc**

Janssen Oncology

**Followed by Live Session Discussion**

**Special Lecture: Tumor Metabolism as a Driver and Treatment Target in Prostate Cancer**

**8:00 AM - 8:20 AM**

**Massimo Loda, MD**

Weill Cornell Medicine

*Introduced and moderated by Howard Soule, PhD*

*Prostate Cancer Foundation*

**Followed by Live Discussion**

**8:20 AM - 8:35 AM** ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

**Session 10: Widening the Aperture; New Approaches for Immunotherapy in Prostate Cancer**

**8:35 AM - 10:35 AM**

**Moderator: Amy Moran, PhD**

Oregon Health & Science University

**Friday, November 5, 2021**

***A T Cell Intrinsic Role for Androgen Receptor Signaling and Immunotherapy Resistance***

**Amy Moran, PhD**

Oregon Health & Science University

***A Review of the Prostate Cancer Treatment Paradigm Exploration with Pembrolizumab and Olaparib***

**Christian H. Poehlein, MD**

Merck Research Laboratories

***Checkpoint Immunotherapy in mCRPC with CDK12-Loss***

**Ajjai Alva, MD**

University of Michigan

***MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients With mCRPC: Preliminary Results of Phase 1 Cohort Expansion***

**Chet Bohac, PharmD, MD, MSc**

MacroGenics, Inc.

***Targeting DLL3 with a Bi-Specific T Cell Engager: AMG 757 in De Novo and Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer***

**Rahul Aggarwal, MD**

University of California, San Francisco

***Advancing the Frontiers of T-Cell Redirecting Agents in Prostate Cancer***

**Oliver Sartor, MD**

Tulane University

**Followed by Live Session Discussion**

10:35 AM - 10:50 AM ***BREAK, Please Return to the Virtual Lobby to Join the Next Session***

**Session 11: Novel Technologies to Overcome the Suppressive Tumor Microenvironment**

**10:50 AM - 12:15 PM**

**Moderator: Marco Gottardis, PhD**

Janssen Research & Development, LLC

***Introduction***

**Marco Gottardis, PhD**

Janssen Research & Development, LLC

**Friday, November 5, 2021**

***Improving CAR Responses against Solid Tumors with Conditional Payload Delivery***

**Gus Zeiner, PhD**

Chimera Bioengineering

***Combining Adenosine Pathway Inhibitors with Immunotherapy Agents in Prostate Cancer***

**Peter Fan, PhD**

Teon Therapeutics

***Mobilizing the Immune System with Bispecific Antibodies and Optimized Cytokines***

**John Desjarlais, PhD**

Xencor

***Microenvironment on Demand (MOD) – A Flexible Droplet-Microfluidic Platform to Accelerate Cell/Antibody Therapy Discoveries***

**Maithreyan Srinivasan, PhD**

Scribe Biosciences

**Followed by Live Session Discussion**

**Closing Remarks**

**12:15 PM - 12:20 PM**

**Howard Soule, PhD**

Prostate Cancer Foundation

**Andrea Miyahira, PhD**

Prostate Cancer Foundation


**12:20 PM - 12:30 PM** ***BREAK, Please Return to the Virtual Lobby to Join the Live Poster Discussion Session***

**VIRTUAL POSTER SESSION 4**

**12:30 PM - 2:00 PM**

**Come to the Poster Hall for Live Discussions  
with Virtual Poster Session 4 Presenters**

***Meeting Adjourned***



## **Program Committee:**

**Program Committee Co-Chair: Howard Soule, PhD** (Prostate Cancer Foundation)

**Program Committee Co-Chair: Andrea Miyahira, PhD** (Prostate Cancer Foundation)

**Andrew Armstrong, MD, ScM** (Duke University)

**Paul Boutros, PhD** (University of California, Los Angeles)

**Marco Gottardis, PhD** (Janssen Research & Development, LLC)

**Michael Hofman, MBBS** (Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia)

**Alicia Morgans, MD, MPH** (Harvard: Dana-Farber Cancer Institute)

**Nima Sharifi, MD** (Cleveland Clinic)

**Kosj Yamoah, MD, PhD** (Moffitt Cancer Center)

Times subject to small changes based on the final event production. All times in U.S. PDT.

***We deeply thank our Retreat supporters for providing funding for this educational initiative.***

